selegiline

(redirected from Anipryl)
Also found in: Dictionary.

selegiline

 [sĕ-lej´ĭ-lēn]
an agent used in treatment of parkinsonism; used as the hydrochloride salt in conjunction with levodopa and carbidopa.

selegiline

(sə-lĕj′ə-lēn′)
n.
A selective monoamine oxidase inhibitor, C13H17N, used transdermally as an antidepressant and in its hydrochloride form in conjunction with levodopa and carbidopa to treat patients with Parkinson's disease.

deprenyl

Alternative pharmacology
A prescription drug used to treat Parkinson’s disease, which has acquired currency among some practitioners of alternative medicine as an anti-ageing substance; deprenyl acts on the substantia nigra., a region of the brain that is believed to age more rapidly than others, by blocking the degradation of dopaminergic neurotransmitters.

selegiline

l-Deprenyl Neuropharmacology A selective monoamine oxidase type B inhibitor which, with l-dopa, may be useful for early symptomatic treatment of parkinsonism

selegiline

A selective MONOAMINE OXIDASE INHIBITOR drug used in the treatment of PARKINSONISM. Selegiline is thought to retard the breakdown of DOPAMINE. Brand names are Eldepryl and Vivapril.
References in periodicals archive ?
Veterinarians may prescribe Anipryl (selegiline), the first FDA-approved drug to control the signs of signs of canine CDS.
For example, products containing amitraz (such as Certifect) should not be used on "medicated" dogs, such as those with diabetes or heart problems; amitraz, a monoamine oxidase inhibitor (MAOI), can be dangerous when combined with antidepressants (such as those used to treat separation anxiety), Anipryl (used for canine cognitive dysfunction and Cushing's disease), and DL-Phenylalanine (DLPA), used to treat chronic pain.
The drug Anipryl (also known as selegiline HCL or L-deprenyl), developed to treat Parkinson's disease in humans, was approved by the FDA in 1999 for use as a treatment for CCD.
Anipryl (selegiline, 1-deprenyl) is the only medication approved for use in dogs to treat CCD.
Amitraz, a monoamine oxidase inhibitor (MAOI), can also be dangerous when combined with certain other drugs, including antidepressants (such as those used to treat separation anxiety), Anipryl (used for canine cognitive dysfunction and Cushing's disease), and DL-Phenylalanine (DL PA), used to treat chronic pain in dogs.
According to Pfizer, which makes the drug, pet owners in studies reported that 69 percent to 75 percent of dogs improved in at least one clinical sign after one month of Anipryl therapy.
He was treated with Anipryl, which was not effective, and then switched to Lysodren (mitotane).
Like all of these other drugs, it should not be combined with monoamine oxidase inhibitors (MAOls), such as selegiline (Anipryl, l-deprenyl) and amitraz (Mitaban, also used in Preventic collars).
Amitraz can be dangerous when combined with antidepressants, such as Prozac (fluoxetine), or with other MAOl inhibitors, such as Anipryl (l-deprenyl, selegiline).
* L-deprenyl (Anipryl or selegeline) is an MAO inhibitor that acts on the pituitary gland itself.